Please login to the form below
PD-1
This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.
NICE turns down Opdivo for adjuvant melanoma therapy
England's cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor as an adjuvant treatment for NHS patients with stage III and IV melanoma – in ... At the moment Opdivo is the only PD-1-targeted cancer immunotherapy
Latest news
-
Novartis wins key adjuvant Taf/Mek approval in Europe
PD-1 inhibitors Opdivo and Keytruda, which have been steadily moving up the treatment pathway in melanoma, have also emerged as a competitive threat to Taf/Mek, although there is now
-
FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer
However, treating the disease from a ‘different angle’, Opdivo can target and block the activity of PD-1, a protein that prevents T cells from recognising and attacking inflamed tissues and ... It’s a significant win for BMS, which is chasing rival
-
Armoured CAR ‘could overwhelm solid tumour resistance’
The approach would also minimise any systemic side effects from giving PD-1 drugs. ... Brentjens. The approach was developed in collaboration with US biotech Eureka Therapeutics, which provided the technology needed to develop the PD-1 antibody component.
-
FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo
Three years ago it joined forces with Bristol-Myers Squib b to test it alongside BMS’PD-1 inhibitor Opdivo (nivolumab) in solid tumours, and has also looked into pairing the ... drug with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) and
-
Regeneron and Bluebird sign $100m cell therapies deal
Regeneron and its long-standing partners Sanofi look set to gain FDA approval for their PD-1 immunotherapy contender, cemiplimab in October, while Bluebird is poised to file its
More from news
Approximately 21 fully matching, plus 246 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have. ... Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are
-
Deal Watch January 2018
Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms. ... used to progress the clinical development of the company's immuno-oncology
-
The good, the bad and the ugly
But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors
-
European venture funding for the life science sector
is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
-
Pharma deals continue to slide
1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US). ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for treatment of cancer.
More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Crescendo Biologics appoints Dr Kevin Johnson as chairman
Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as ... 1 Humabodies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
A stumble, but not a fall – what’s next for Opdivo?
Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1
-
Research Partnership
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director. ... Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Sudler London - Senior Medical Writer
-
Competitive
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Sudler London - Account Director
-
Competitive
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Account Manager
-
Negotiable
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
Research Partnership
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
